Valuation : Positron Corporation

Market Cap 55.51M 47.79M 44.88M 40.98M 76.91M 5.28B 77.45M 532M 207M 2.68B 208M 204M 8.87B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 54.37M 46.82M 43.96M 40.14M 75.34M 5.17B 75.87M 521M 202M 2.62B 204M 200M 8.69B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.36%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
President 53 27/02/2018
Sales & Marketing - 24/06/2022
Corporate Officer/Principal 40 25/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-1.00%-1.42%-26.30%-4.82% 12.82B
+4.24%-2.30%+14.39%+9.32% 4.41B
+1.69%-4.06%-39.90%-56.34% 1.23B
-0.27%-0.90%-37.68%-41.10% 1.16B
-0.79%-0.92%+20.60%+86.85% 1.11B
+1.52%+0.30%-36.15% - 1.05B
-0.79%+7.35% - - 1.04B
-0.19%-3.87%+28.33%+109.66% 536M
-1.52%+0.17%+60.00% - 297M
Average +0.32%+0.90%-2.09%+17.26% 2.63B
Weighted average by Cap. +0.29%-0.40%-15.42%+0.83%

Financials

2024 2025
Net sales 588K 506K 475K 434K 814K 55.9M 820K 5.63M 2.19M 28.36M 2.21M 2.16M 93.88M 461K 397K 373K 341K 639K 43.91M 644K 4.42M 1.72M 22.27M 1.73M 1.69M 73.74M
Net income -2.38M -2.05M -1.92M -1.76M -3.3M -226M -3.32M -22.79M -8.86M -115M -8.93M -8.74M -380M -10.6M -9.13M -8.57M -7.83M -14.69M -1.01B -14.79M -102M -39.49M -512M -39.8M -38.94M -1.69B
Net Debt 1.42M 1.23M 1.15M 1.05M 1.97M 136M 1.99M 13.65M 5.3M 68.75M 5.35M 5.23M 228M -1.14M -978K -919K -839K -1.57M -108M -1.59M -10.89M -4.23M -54.84M -4.26M -4.17M -182M
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
-